Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A single-center, open-access study to evaluate drug interactions between XNW3009, febuxostat, and colchicine in patients with gout
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1 | Other | Colchicine 0.5 mg Oral Tablet Day-7~Day25 qd, Febuxostat 40 mg Oral Tablet Day1 and Day14 qd, XNW3009 0.5 mg Oral Tablet Day8~Day21 qd. Interventions: Drug: Colchicine Drug: Febuxostat Drug: XNW3009 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Colchicine | Drug | Colchicine0.5 mg Oral Tablet Day-7~Day25 qdďźFebuxostat 40 mg Oral Tablet Day1 and Day14 qdďźXNW3009 0.5 mg Oral Tablet Day8 and Day21 qd |
|
| Measure | Description | Time Frame |
|---|---|---|
| Observed maximum concentration at steady state (Cmax,ss) | To evaluate the maximum concentration at steady state of oral XNW3009 tablets, febuxostat, and colchicine in patients with gout | 100 days |
| Observed area under the concentration-time curve from zero to the end of the dosing interval at steady state (AUCss) | To evaluate the AUCss of oral XNW3009 tablets, febuxostat, and colchicine in patients with gout | 100 days |
| Measure | Description | Time Frame |
|---|---|---|
| Time to Maximum Serum Concentration (Tmax) | To evaluate the Tmax of oral XNW3009 tablets, febuxostat and colchicine in patients with gout | 100 days |
| Mean Terminal Phase Half-life (t1/2) | To evaluate the t1/2 of XNW3009 tablets, febuxostat and colchicine in gout patients |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yu Cao, Doctor | Contact | 18661809090 | caoyu1767@126.com | |
| Yi Xu, Doctor | Contact | 18661809455 | xuyi198861@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Yi Xu, Doctor | The Affiliated Hospital of Qingdao University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Affiliated Hospital of Qingdao University | Recruiting | Qingdao | Shandong | 266003 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006073 | Gout |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D000070657 | Crystal Arthropathies |
Not provided
Not provided
| ID | Term |
|---|---|
| D003078 | Colchicine |
| ID | Term |
|---|---|
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 100 days |
| Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) | Data for number of participants who presented one or more adverse events (serious or non serious) was reported. An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition. | 100 days |
| Serum or urine Uric Acid Level | Change in Serum or urine Uric Acid Level | 100 days |
| Serum or urine Creatinine | Change in Serum or urine Creatinine | 100 days |
| Number of Participants With Clinically Significant Laboratory Test Abnormalities | Investigator judged clinical significance of laboratory test abnormalities. | 100 days |
| D012216 |
| Rheumatic Diseases |
| D011686 | Purine-Pyrimidine Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |